FME logo

Fresenius Medical Care AG Stock Price

XTRA:FME Community·€11.4b Market Cap
  • 3 Narratives written by author
  • 2 Comments on narratives written by author
  • 37 Fair Values set on narratives written by author

FME Share Price Performance

€0
-47.94 (-100.00%)
€43.69
Fair Value
€0
-47.94 (-100.00%)
Price €0

FME Community Narratives

·
Fair Value €43.69 3.2% undervalued intrinsic discount

Aging Demographics And Home Care Trends Will Shape Future Profit Opportunities

0users have liked this narrative
2users have commented on this narrative
20users have followed this narrative
·
Fair Value €31 36.4% overvalued intrinsic discount

The Shift To Home Dialysis Will Erode Core Revenues

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value €64.18 34.1% undervalued intrinsic discount

Aging, Diabetes, And Digital Health Will Fortify Home Dialysis Care

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
€43.69
3.2% undervalued intrinsic discount
Revenue
2.98% p.a.
Profit Margin
6.02%
Future PE
8.86x
Price in 2029
€52.2
€31
36.4% overvalued intrinsic discount
Revenue
2.11% p.a.
Profit Margin
4.36%
Future PE
8.91x
Price in 2029
€37.03

Trending Discussion

Updated Narratives

FME logo

FME: Buybacks And Digital Dialysis Platform Will Support Future Returns

Fair Value: €43.69 3.2% undervalued intrinsic discount
20 users have set this as their fair value
2 users have commented on this narrative
0 users have liked this narrative
FME logo

FME: Value Based Kidney Care Success Will Drive Long Term Upside

Fair Value: €64.18 34.1% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
FME logo

FME: Higher Discount Rate And Flat 2026 Outlook Will Pressure Returns

Fair Value: €31 36.4% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued established dividend payer.

1 Risk
5 Rewards

Fresenius Medical Care AG Key Details

€19.4b

Revenue

€14.3b

Cost of Revenue

€5.0b

Gross Profit

€4.1b

Other Expenses

€944.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 04, 2026
3.52
25.96%
4.88%
53.2%
View Full Analysis

About FME

Founded
1996
Employees
108165
CEO
Helen Giza
WebsiteView website
www.freseniusmedicalcare.com

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Recent FME News & Updates

Narrative Update Jun 28

FME: Buybacks And Digital Dialysis Platform Will Support Future Returns

The latest analyst update on Fresenius Medical Care trims the price target by about €1, reflecting a slightly higher discount rate along with adjusted assumptions for revenue, profit margin and future P/E expectations. What’s in the News for Fresenius Medical Care Fresenius Medical Care is highlighted alongside DaVita in recent coverage of the global dialysis market.
Narrative Update Jun 14

FME: Value Based Kidney Care Success Will Drive Long Term Upside

Analysts have trimmed their price target for Fresenius Medical Care to about €64 from roughly €65, reflecting updated views on fair value, a higher discount rate, more muted revenue growth assumptions, slightly lower profit margin expectations and a reduced future P/E multiple. What's in the News Interwell Health, Fresenius Medical Care's value based care segment, reported top quality scores in the CMS Kidney Care Choices Model and delivered $273 million in shared savings over three years, highlighting performance in value based kidney care (source: Interwell Health news release).

Recent updates

No updates